Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples

Fernández-Natal I, Sáez-Nieto JA, Medina-Pascual MJ, Albersmeier A, Valdezate S, Guerra-Laso JM, Rodríguez H, Marrodán T, Parras T, Tauch A, Soriano F (2013)
New microbes and new infections 1(3): 35-40.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Fernández-Natal, I; Sáez-Nieto, J A; Medina-Pascual, M J; Albersmeier, A; Valdezate, S; Guerra-Laso, J M; Rodríguez, H; Marrodán, T; Parras, T; Tauch, AndreasUniBi; Soriano, F
Abstract / Bemerkung
During a 12-year period, Dermabacter hominis was isolated from 21 clinical samples belonging to 14 patients attending a tertiary hospital in León, Spain. Samples included blood cultures (14), peritoneal dialysis catheter exit sites (three), cutaneous abscesses (two), an infected vascular catheter (one) and a wound swab (one). Identification was made by API Coryne™ V2.0, Biolog™ GP2 and 16S rRNA gene amplification. Six febrile patients had positive blood cultures (one, two or three sets) and all of them were treated with teicoplanin (two patients), vancomycin, ampicillin plus gentamicin, amoxicillin/clavulanic acid and ciprofloxacin (one each). An additional patient with a single positive blood culture was not treated, the finding being considered non-significant. In the remaining seven patients the organism was isolated from a single specimen and three of them received antimicrobial treatment (ciprofloxacin, ceftriaxone plus vancomycin and amoxicillin/clavulanic acid). At least ten patients had several underlying diseases and conditions, and no direct mortality was observed in relation to the isolated organism. All isolates were susceptible to vancomycin, rifampin and linezolid. Resistance to other antibiotics varied: erythromycin (100%), clindamycin (78.5%), ciprofloxacin (21.4%) and gentamicin, quinupristin-dalfopristin, benzylpenicillin and imipenem 7.1% each. Thirteen isolates were highly resistant to daptomycin with MICs ranging from 8 to 48 (MIC90 = 32 mg/L); only one was daptomycin-sensitive (MIC = 0.19 mg/L).
Erscheinungsjahr
2013
Zeitschriftentitel
New microbes and new infections
Band
1
Ausgabe
3
Seite(n)
35-40
ISSN
2052-2975
Page URI
https://pub.uni-bielefeld.de/record/2703752

Zitieren

Fernández-Natal I, Sáez-Nieto JA, Medina-Pascual MJ, et al. Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. New microbes and new infections. 2013;1(3):35-40.
Fernández-Natal, I., Sáez-Nieto, J. A., Medina-Pascual, M. J., Albersmeier, A., Valdezate, S., Guerra-Laso, J. M., Rodríguez, H., et al. (2013). Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. New microbes and new infections, 1(3), 35-40. doi:10.1002/2052-2975.31
Fernández-Natal, I., Sáez-Nieto, J. A., Medina-Pascual, M. J., Albersmeier, A., Valdezate, S., Guerra-Laso, J. M., Rodríguez, H., Marrodán, T., Parras, T., Tauch, A., et al. (2013). Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. New microbes and new infections 1, 35-40.
Fernández-Natal, I., et al., 2013. Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. New microbes and new infections, 1(3), p 35-40.
I. Fernández-Natal, et al., “Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples”, New microbes and new infections, vol. 1, 2013, pp. 35-40.
Fernández-Natal, I., Sáez-Nieto, J.A., Medina-Pascual, M.J., Albersmeier, A., Valdezate, S., Guerra-Laso, J.M., Rodríguez, H., Marrodán, T., Parras, T., Tauch, A., Soriano, F.: Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. New microbes and new infections. 1, 35-40 (2013).
Fernández-Natal, I, Sáez-Nieto, J A, Medina-Pascual, M J, Albersmeier, A, Valdezate, S, Guerra-Laso, J M, Rodríguez, H, Marrodán, T, Parras, T, Tauch, Andreas, and Soriano, F. “Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples”. New microbes and new infections 1.3 (2013): 35-40.

3 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Antiproliferative and Antibacterial Activities of Cirsium scabrum from Tunisia.
Sahli R, Rivière C, Dufloer C, Beaufay C, Neut C, Bero J, Hennebelle T, Roumy V, Ksouri R, Quetin-Leclercq J, Sahpaz S., Evid Based Complement Alternat Med 2017(), 2017
PMID: 28785293
High-quality genome sequencing and description of Dermabacter indicis sp. nov.
Lo CI, Sankar SA, Ehounoud CB, Mediannikov O, Labas N, Caputo A, Raoult D, Fournier PE, Fenollar F., New Microbes New Infect 11(), 2016
PMID: 27081494

30 References

Daten bereitgestellt von Europe PubMed Central.

Taxonomic studies on some human cutaneous coryneform bacteria: description of Dermabacter hominis gen.nov., sp.nov
Jones D, Collins MD., 1988
Characteristics of CDC group 3 and group 5 coryneform bacteria isolated from clinical specimens and assignment to the genus Dermabacter.
Funke G, Stubbs S, Pfyffer GE, Marchiani M, Collins MD., J. Clin. Microbiol. 32(5), 1994
PMID: 8051248
Recognition of Dermabacter hominis, formerly CDC fermentative coryneform group 3 and group 5, as a potential human pathogen.
Gruner E, Steigerwalt AG, Hollis DG, Weyant RS, Weaver RE, Moss CW, Daneshvar M, Brenner DJ., J. Clin. Microbiol. 32(8), 1994
PMID: 7989543
Evaluation of the Andromas matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli.
Farfour E, Leto J, Barritault M, Barberis C, Meyer J, Dauphin B, Le Guern AS, Lefleche A, Badell E, Guiso N, Leclercq A, Le Monnier A, Lecuit M, Rodriguez-Nava V, Bergeron E, Raymond J, Vimont S, Bille E, Carbonnelle E, Guet-Revillet H, Lecuyer H, Beretti JL, Vay C, Berche P, Ferroni A, Nassif X, Join-Lambert O., J. Clin. Microbiol. 50(8), 2012
PMID: 22692743
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis.
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD; NISC Comparative Sequence Program, Murray PR, Turner ML, Segre JA, Mullikin J, Thomas J, Blakesley R, Young A, Chu G, Ramsahoye C, Lovett S, Han J, Legaspi R, Sison C, Montemayor C, Gregory M, Hargrove A, Johnson T, Riebow N, Schmidt B, Novotny B, Gupta J, Benjamin B, Brooks S, Coleman H, Ho SL, Schandler K, Stantripop M, Maduro Q, Bouffard G, Dekhtyar M, Guan X, Masiello C, Maskeri B, McDowell J, Park M, Vemulapalli M., Genome Res. 22(5), 2012
PMID: 22310478
Topographical and temporal diversity of the human skin microbiome.
Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC; NISC Comparative Sequencing Program, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA., Science 324(5931), 2009
PMID: 19478181
Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition.
Li E, Hamm CM, Gulati AS, Sartor RB, Chen H, Wu X, Zhang T, Rohlf FJ, Zhu W, Gu C, Robertson CE, Pace NR, Boedeker EC, Harpaz N, Yuan J, Weinstock GM, Sodergren E, Frank DN., PLoS ONE 7(6), 2012
PMID: 22719818
Cerebral Dermabacter hominis abscess.
Bavbek M, Caner H, Arslan H, Demirhan B, Tuncbilek S, Altinors N., Infection 26(3), 1998
PMID: 9646113
Bacteremia by Dermabacter hominis, a rare pathogen.
Gomez-Garces JL, Oteo J, Garcia G, Aracil B, Alos JI, Funke G., J. Clin. Microbiol. 39(6), 2001
PMID: 11376092
Peritoneal dialysis-associated peritonitis caused by Dermabacter hominis.
Radtke A, Bergh K, Oien CM, Bevanger LS., J. Clin. Microbiol. 39(9), 2001
PMID: 11526195
Chronic osteomyelitis due to Actinomyces neuii subspecies neuii and Dermabacter hominis.
Van Bosterhaut B, Boucquey P, Janssens M, Wauters G, Delmee M., Eur. J. Clin. Microbiol. Infect. Dis. 21(6), 2002
PMID: 12111611
A patient with fatal septicemia caused by a rare pathogen Dermabacter hominis
Lee H-J, Cho C-H, Kwon M-J, Nam M-H, Lee K-N, Lee C-K., 2011
Antimicrobial susceptibility patterns of some recently established coryneform bacteria.
Funke G, Punter V, von Graevenitz A., Antimicrob. Agents Chemother. 40(12), 1996
PMID: 9124857
Natural antibiotic susceptibility of recently established coryneform bacteria.
Troxler R, Funke G, Von Graevenitz A, Stock I., Eur. J. Clin. Microbiol. Infect. Dis. 20(5), 2001
PMID: 11453591
In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria.
Gomez-Garces JL, Alos JI, Tamayo J., Int. J. Antimicrob. Agents 29(6), 2007
PMID: 17475450
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering RC Jr., Antimicrob. Agents Chemother. 30(4), 1986
PMID: 3024560
In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.
Barry AL, Fuchs PC, Brown SD., Antimicrob. Agents Chemother. 45(6), 2001
PMID: 11353654
Activity of daptomycin and three comparator agents against non-diphtheriae Corynebacterium isolates of clinical interest.
Navas J, Salas C, Calvo J, Martinez-Martinez L., J. Antimicrob. Chemother. 67(3), 2011
PMID: 22129591
16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates.
Drancourt M, Bollet C, Carlioz A, Martelin R, Gayral JP, Raoult D., J. Clin. Microbiol. 38(10), 2000
PMID: 11015374

AUTHOR UNKNOWN, 2010
Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland.
Seppala H, Nissinen A, Yu Q, Huovinen P., J. Antimicrob. Chemother. 32(6), 1993
PMID: 8144429
Complete genome sequence, lifestyle, and multi-drug resistance of the human pathogen Corynebacterium resistens DSM 45100 isolated from blood samples of a leukemia patient.
Schroder J, Maus I, Meyer K, Wordemann S, Blom J, Jaenicke S, Schneider J, Trost E, Tauch A., BMC Genomics 13(), 2012
PMID: 22524407
Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.
Sierra JM, Martinez-Martinez L, Vazquez F, Giralt E, Vila J., Antimicrob. Agents Chemother. 49(5), 2005
PMID: 15855486
Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.
Silverman JA, Perlmutter NG, Shapiro HM., Antimicrob. Agents Chemother. 47(8), 2003
PMID: 12878516
Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.
Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC Jr, Eliopoulos GM., PLoS ONE 7(1), 2012
PMID: 22238576
Genetic basis for in vivo daptomycin resistance in enterococci.
Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM., N. Engl. J. Med. 365(10), 2011
PMID: 21899450
Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium.
Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G., Antimicrob. Agents Chemother. 56(11), 2012
PMID: 22948885
Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms.
D'Costa VM, Mukhtar TA, Patel T, Koteva K, Waglechner N, Hughes DW, Wright GD, De Pascale G., Antimicrob. Agents Chemother. 56(2), 2011
PMID: 22083474

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Quellen

PMID: 25356327
PubMed | Europe PMC

Suchen in

Google Scholar